Pharming Group (EURONEXT:PHARM), (NASDAQ:PHAR) is a biopharmaceutical company engaged in the development, production, and commercialization of innovative treatments for rare diseases and unmet medical needs. Its portfolio focuses on therapies in the fields of hereditary angioedema and Pompe disease, leveraging its expertise in protein replacement therapies. The company is renowned for Ruconest®, its lead product for the treatment of hereditary angioedema. Pharming Group NV is dedicated to enhancing patient care and improving quality of life through continuous research and development. With a commitment to sustainability and ethical practices, Pharming aims to expand its product offering and reach to address the needs of patients globally, striving for excellence in everything they do, with the ultimate goal of becoming a beacon of hope for those facing rare and challenging diseases.